Stereotactic Body Radiotherapy for Localized Ureter Transitional Cell Carcinoma: Three Case Reports

Maehata, Yoshiyasu; Kuriyama, Kinya; Aoki, Shin; Araya, Masayuki; Marino, Kan; Oda, Hiroshi

doi:10.1155/2015/519897

Cited by 7 publications

(6 citation statements)

References 8 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding safety, two individual studies published in the last few years were case reports of the use of stereotactic body radiotherapy (SBRT) for the treatment of UTUC. Maehata and Evans both reported their experience using SBRT in elderly patients with medically inoperable UTUC, and no acute or late adverse events were observed in any of the three cases (16,17). In the present study, our cases supported the clinical experience of Maehata and Evans.…”

Section: Discussionsupporting

confidence: 86%

Radiation therapy for nonmetastatic medically inoperable upper-tract urothelial carcinoma

et al. 2021

View full text Add to dashboard Cite

Background: The standard management for upper urinary tract urothelial carcinoma (UTUC) is radical nephroureterectomy (RNU). However, some patients cannot undergo this procedure for several reasons, such as unresectable disease, old age, and multiple comorbidities. Our study explored the potential safety and effectiveness of radiotherapy as a curative treatment for UTUC patients unfit for surgery. Methods:The data of patients treated with radiotherapy between December 2017 and November 2019 were retrospectively reviewed. For the literature review, computerized PubMed Medline, Index Medicus, and Web of Science databases and reference lists from the identified publications of interest were used. And "upper-tract urothelial carcinoma" and "radiotherapy" were used as key words in the search. Results:We describe 8 patients with UTUC who were treated with radiotherapy. The median follow-up time was 13.5 months (range, 8.6-30.9 months). Local tumor control was achieved in all patients. However, distant metastases were observed in 2 patients with T3-4/N+ status. One patient had T4 status and the other had N2+ status. The patients died of tumor progression at 15.0 and 17.7 months. In addition, the other 6 patients who were still alive had relatively early-stage tumors without nodal involvement. Regarding acute toxicity, according to the CTCAE v5.0, mild side effects were noted, including grade 1 nausea and diarrhea.Four patients developed mild anemia, generally of grade 1-2. One patient experienced grade 3 anemia, but it was manageable and improved with symptomatic support. In addition, no grade 4 acute or late toxicities were observed. No significant long-term impairment of renal function occurred.Conclusions: For patients with nonmetastatic UTUC who are not suitable for surgery, radiotherapy is a safe treatment and can achieve good local tumor control.

show abstract

Section: Discussionsupporting

confidence: 86%

Radiation therapy for nonmetastatic medically inoperable upper-tract urothelial carcinoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Maehata et al reported on their experience with aggressive hypofractionated radiation therapy, using between 50 and 60 Gy in 10 fractions in 3 elderly patients with medically inoperable UUTUC. 26 In all 3 cases, this hypofractionated regimen was effective at controlling the treated tumor. One patient, who had a primary lesion in the distal ureter, experienced an out-of-field bladder recurrence 22 months after treatment.…”

Section: Discussionmentioning

confidence: 87%

Stereotactic body radiation therapy for medically inoperable, clinically localized, urothelial carcinoma of the renal pelvis: A case report

Evans

Hansen

Tollefson

et al. 2018

Advances in Radiation Oncology

View full text Add to dashboard Cite

“…Maehata et al reported 3 cases of inoperable localized T2N0M0 ureter carcinoma treated with stereotactic body radiotherapy (SBRT). In their study, no acute adverse events were observed, and tumor control was obtained in 2 of the 3 patients (15). When high-dose local irradiation is delivered to T1-2 tumors, local tumor control can be achieved.…”

Section: Discussionmentioning

confidence: 93%

“…Primary tumor sites included the renal pelvis (n=3) and ureter (n=2). In reference to previous reports for RT for cancer of the upper urinary tract, clinical staging but not pathological staging was used in the present study (15,16). Two patients with stage IV (case 3 and case 5) received systemic chemotherapy and the response to the chemotherapy was so good that these patients were sent to our hospital to obtain a control of the localized residual tumors.…”

Section: Methodsmentioning

confidence: 99%

Proton beam therapy for renal pelvis and ureter cancer: A report of 5 cases and a literature review

et al. 2019

View full text Add to dashboard Cite

Standard treatment for localized renal pelvis and ureter cancer is surgery. Previously, the primary role of radiation therapy (RT) in cancer treatment was to control pain and hemostasis as palliative or as adjuvant therapy following surgery. In this report, we describe 5 patients with the disease treated with proton beam therapy (PBT) as curative treatment. Between September 2009 and July 2013, 5 males with renal pelvis (n=3) or ureter (n=2) cancer were treated by PBT with hypofractionated [72.6 Gy relative biological effectiveness (RBE)/22 fractions] or conventional [64–66 Gy (RBE)/32–33 fractions] fractionation. The median patient age was 72 years (range, 59–85 years). Three patients were deemed unfit for surgery. Local hypofractionated PBT was performed in 2 patients with T1-2N0M0 diseases, while prophylactic lymph node irradiation using a patch irradiation technique was performed for the remaining 3 patients, who had T3-4 disease. Two patients with T3-4 disease received chemotherapy prior to definitive PBT. No serious acute or late toxicities were observed in any patient. Local tumor control was achieved in 3 patients (60%); however, distant metastases were observed in 2 patients. Four of the five patients (80%) evaluated in the present study survived for >3 years. The data is limited; however, PBT appears to be a potential option for patients with renal pelvis or ureter cancer, especially for those who are unsuitable for radical surgery.

show abstract

Stereotactic Body Radiotherapy for Localized Ureter Transitional Cell Carcinoma: Three Case Reports

Cited by 7 publications

References 8 publications

Radiation therapy for nonmetastatic medically inoperable upper-tract urothelial carcinoma

Radiation therapy for nonmetastatic medically inoperable upper-tract urothelial carcinoma

Stereotactic body radiation therapy for medically inoperable, clinically localized, urothelial carcinoma of the renal pelvis: A case report

Proton beam therapy for renal pelvis and ureter cancer: A report of 5 cases and a literature review

Contact Info

Product

Resources

About